Effect of Intratumoral Injection of 10B-Immunoliposome on BNCT for Growth Inhibition of Human Pancreatic Cancer Grafts in Nude Mice

  • Hironobu Yanagië
  • Toshio Tomita
  • Hisao Kobayashi
  • Yuzo Fujii
  • Yoshiyuki Saegusa
  • Masazumi Eriguchi
  • Tooru Kobayashi
  • Keiji Kanda
  • Kouji Ono

Abstract

Cytotoxic effect of boron neutron capture therapy (BNCT) is due to the nuclear reaction between 10B and thermal neutrons. This nuclear reactions as followed
$${}^{10}B + {}^1n \to {}^4He + {}^7Li + 2.4MeV$$
The heavy charged particles from the 10B (n, α) 7Li reaction have a range of approximately 10 µm in tissue and are known to have a high relative biological effectiveness1). Therefore, it is theoretically possible to kill the tumor cells without affecting the adjacent normal cells, if effi-cient 10B atoms could be selectively accumulated in the tumor cells. BNCT has been applied clinically for treatment of malignant brain tumors2) or malignant melanoma3).

Keywords

Thermal Neutron Tumor Weight Boron Neutron Capture Therapy Relative Biological Effectiveness Intratumoral Injection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. I. Kruger, P. G. Some biological effects of nuclear disintegration products on neoplastic tissue. Proc. Natl. Acad. Sci. USA., 26: 181–192, 1940.CrossRefGoogle Scholar
  2. 2.
    . Hatanaka, H., Kamano, S., Amano, K., Hojo, S., Sano, K., Egawa, S., et. al. Clinical experience of boron-neutron capture therapy for gliomas: a comparison with conventional chemo-immuno-radiotherapy. In: Hatanaka, H., editor. Boron neutron capture therapy for tumors. Niigata, Japan: Nishimura Co., Ltd., 349–378, 1986.Google Scholar
  3. 3.
    . Mishima, Y., Ichihashi, M., Tsuji, M., Hatta, S., Ueda, M., Honda, C., et. al. Treatment of malignant melanoma by single thermal neutron capture therapy with melanoma-seeking 10B-compound. Lancet, 2: 388–389, 1989.PubMedCrossRefGoogle Scholar
  4. 4.
    Yanagie, H., Tomita, T., Kobayashi, H., Fujii, Y., Takahashi, T., Hasumi, K., et. al. Application of boronated anti-CEA immuno-liposome to tumour cell growth inhibition in in vitro boron neutron capture therapy model. Br.1. Cancer, 63: 522–526, 1991.Google Scholar
  5. 5.
    . Tomita, T., Watanabe, M., Takahashi, T., Kumai, K., Tadakuma,T., & Yasuda, T. Temperature-sensitive release ofadriamycin, an amphiphilic antitumor agent, from dipalmitoylphosphatidyl-choline-cholesterol liposomes.. Biochimica et Biophysica Acta, 978: 185–190, 1989.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Hironobu Yanagië
    • 1
  • Toshio Tomita
    • 2
  • Hisao Kobayashi
    • 3
  • Yuzo Fujii
    • 1
  • Yoshiyuki Saegusa
    • 1
  • Masazumi Eriguchi
    • 1
  • Tooru Kobayashi
    • 4
  • Keiji Kanda
    • 4
  • Kouji Ono
    • 4
  1. 1.Department of Clinical Oncology Institute of Medical ScienceUniversity of TokyoMinato-ku Tokyo 108Japan
  2. 2.Laboratory for Culture Collection Institute of Medical ScienceUniversity of TokyoMinato-ku Tokyo 108Japan
  3. 3.Institute of Atomic EnergyRikkyo UniversityKanagawa 240-01Japan
  4. 4.Research Reactor InstituteKyoto UniversityKumatori, Osaka 590-04Japan

Personalised recommendations